Hims Alternatives: How to Compare GLP-1 Telehealth Options

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This overview is from the PlexusDx Education Hub, our resource for making sense of GLP-1 therapies, weight-management protocols, and the genetics behind them. Browse all Peptides & GLP-1 education

This is an independent editorial review. PlexusDx has no commercial relationship with Hims or its parent company, and no affiliate links or compensation are involved.

Anyone weighing Hims quickly discovers it is one option among many in a crowded GLP-1 telehealth field. Rather than rank services, this review, current as of April 2026, gives you a framework for comparing the alternatives on their own terms. It is fair-balance context, not a buying recommendation.

The GLP-1 telehealth landscape

The category is populated by subscription telehealth brands that connect patients to licensed providers and, if eligible, to a prescription. Hims (Hims & Hers Health) operates as subscription telehealth within this landscape. What separates one program from another is less the marketing and more the underlying model: who prescribes, which pharmacy fulfills, and what the subscription actually bundles. Two brands can advertise similar-sounding programs while differing sharply on those points, which is exactly why a structured comparison beats a surface impression.

How to compare programs like Hims

A useful comparison rests on a few consistent questions. Is the prescriber a physician, nurse practitioner, or physician assistant? Is the pharmacy a retail dispensary or a 503A compounder? Is pricing transparent up front or revealed after intake? And does clinical follow-up support dose titration over time? Applying the same checklist to every alternative turns a confusing field into a like-for-like assessment.

Retail versus compounded pathways

The single biggest dividing line among alternatives is the dispensing pathway. Some programs route prescriptions to a retail pharmacy for FDA-approved brand products; others use a 503A compounding pharmacy for compounded semaglutide or tirzepatide. That choice affects regulatory footing, cost, and availability, so it belongs at the center of any comparison. Verify how any program handles it, including at Hims's official website.

What the evidence covers

Whatever the brand, the pharmacology traces back to the same compound class: GLP-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide, and the dual GIP/GLP-1 agonist tirzepatide. Landmark studies include STEP for semaglutide (NEJM, 2021), SURMOUNT for tirzepatide (NEJM, 2022), and SURMOUNT-OSA for tirzepatide in obstructive sleep apnea (NEJM, 2024). Endpoints and populations vary, and outcomes are individual.

Where a genetics-first approach fits

Most alternatives share one blind spot: none map the genetic architecture underneath a GLP-1 response. Variants in FTO (fat-mass and obesity-associated), GLP1R (the receptor these compounds target), MC4R (satiety and energy balance), and TCF7L2 (glucose homeostasis) describe your baseline metabolic terrain. They are pathway-level and do not predict response to any specific compound, but they add context no program captures.

PlexusDx fits here as a genetics-first option that also offers semaglutide and tirzepatide through its Weight Management Protocols — Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including FTO, MC4R, and TCF7L2 — the test before you invest approach to choosing among alternatives.

Not affiliated: PlexusDx is not affiliated with Hims and has no commercial relationship with the companies reviewed in this article.

Related reading on PlexusDx: What Is GLP 1, GLP 1 What Is, GLP 1 Receptor Agonist, GLP 1 Drugs.

Disclaimer: This article is educational. PlexusDx is not affiliated with Hims and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols, and this review compares approaches in the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways; it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

See how PlexusDx compares: explore the Weight Management Protocols for semaglutide and tirzepatide with genetic context, or take the Precision Peptide Genetic Test to understand your GLP-1 pathway before choosing.

Frequently Asked Questions

What should I compare when weighing Hims against alternatives?

Look at the prescriber type, whether the pharmacy is retail or compounding, how transparent pricing is before intake, and how follow-up supports dose titration. Applying the same set of questions to each program produces a fair, like-for-like comparison rather than a marketing-driven impression.

Are compounded and brand GLP-1 programs interchangeable?

Not exactly. Retail pathways dispense FDA-approved brand products, while 503A compounding pharmacies supply compounded semaglutide or tirzepatide. The two differ in regulatory standing, cost, and availability, so the dispensing pathway is one of the most important factors when comparing alternatives.

Does any telehealth alternative account for genetics?

Most do not. Programs typically prescribe without mapping variants like FTO and MC4R, or TCF7L2. A genetics-first option adds that upstream context, though the Precision Peptide Genetic Test describes baseline biology rather than predicting response to any specific compound or program.

How does PlexusDx differ from Hims?

PlexusDx pairs its semaglutide and tirzepatide protocols with the Precision Peptide Genetic Test, adding pathway-level genetic context that most telehealth-only programs like Hims do not offer alongside the medication itself. The distinction is upstream insight into your own baseline biology, not simply a different subscription structure or price point.

Continue exploring the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.